Kus, CananOzer, EzgiKorkmaz, YesimYurtcu, ErkanDagalp, Rukiye2023-05-112023-05-1120181389-5575http://hdl.handle.net/11727/9005Background & Method: In this ongoing research, it is aimed to investigate the synthesis, structure identification and effects on urokinase-type plasminogen activators (uPA) and its receptor levels of 4-(3H-imidazo[4,5-b] pyridin-2-yl)-N-substituted benzamide and benzamidine derivatives. uPA levels obtained from 4b and 7d administration were similar to 5-FU (5-fluorouracil) for colorectal carcinoma cells (p<0.05). 4b and 7d significantly reduced uPAR (urokinase-type plasminogen activator receptor) levels on both cell lines (p<0.05). Conclusion: uPAR levels obtaining from 4b and 7d administration were similar to 5-FU for both cell lines colorectal (Colo205, CCL-222) and hepatocellular (HepG2, CCL-23) carcinoma cells (p<0.05).enginfo:eu-repo/semantics/closedAccessImidazopyridinebenzamidebenzamidineurinary plasminogen activatoruPARupamostatarticle1820175317580004518178000052-s2.0-85057451499